<DOC>
	<DOCNO>NCT02215954</DOCNO>
	<brief_summary>To demonstrate non inferiority ) `` FE 999169 Split Dosing Schedule '' ( one dose day second dose day colonoscopy ) b ) `` FE 999169 Day Before Dosing Schedule '' ( two dos day colonoscopy ) `` Niflec On Day Dosing Schedule '' subject require colonoscopy .</brief_summary>
	<brief_title>A Phase III Study With FE 999169 Versus Niflec Colon Cleansing</brief_title>
	<detailed_description />
	<criteria>Japanese patient , age 20 80 year inclusive , require colonoscopy Female patient postmenopausal ( woman â‰¥45 year menstrual period least 12 month without alternative medical cause ) , surgically sterile , use medically approve contraception , throughout trial period . Fertile female patient must confirm negative pregnancy test screen randomization Patients must equal 3 spontaneous bowel movement per week prior colonoscopy Written inform consent obtain prior studyrelated procedure Acute surgical abdominal condition , acute intestinal obstruction intestinal perforation , diverticulitis , appendicitis . If intestinal obstruction perforation suspect , perform appropriate diagnostic study rule condition Active ( acute/exacerbation of/severe/uncontrolled ) Inflammatory Bowel Disease ( IBD ) Any prior colorectal surgery , exclude appendectomy , haemorrhoid surgery prior endoscopic procedure Colon disease ( history colonic cancer , toxic megacolon , idiopathic pseudoobstruction , hypomotility syndrome ) Gastrointestinal disorder ( active ulcer , outlet obstruction , retention , gastroparesis , ileus ) Upper gastrointestinal surgery ( gastric resection , gastric banding , gastric bypass ) Uncontrolled angina and/or Myocardial Infarction ( MI ) within last 3 month , Congestive Heart Failure ( CHF ) , uncontrolled hypertension Renal insufficiency ( serum creatinine , serum potassium value exceed upper limit normal range screen ) history event Participation clinical trial past 3 month Any clinically significant laboratory value screening , include preexist electrolyte abnormality , base clinical history investigator feel may affect study evaluation Hypersensitivity active ingredient Subject suspend prohibit medication Subjects appropriate participate study deem investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>